APO Research
Talk to an analyst

APO RESEARCH · REPORT

API Drug Development Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global API Drug Development Service Market Outlook and Growth Opportunities 2026

3 May 2026197 pages

Choose your research edition.

Industry ResearchAPI Drug Development Service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal API Drug Development Service Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal API Drug Development Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal API Drug Development Service Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal API Drug Development Service Market Analysis and Forecast 2026-2032244 pages · $4,950 USD

Market perspective

The global API Drug Development Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for API Drug Development Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for API Drug Development Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for API Drug Development Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the API Drug Development Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the API Drug Development Service market include Lonza, Patheon, Catalent, Carbogen Amcis, Sterling Pharma Solutions, Cambrex, CordenPharma, Eurofins Scientific and Malvern Panalytical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global API Drug Development Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of API Drug Development Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents API Drug Development Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global API Drug Development Service market.

API Drug Development Service Segment by Company

Lonza

Patheon

Catalent

Carbogen Amcis

Sterling Pharma Solutions

Cambrex

CordenPharma

Eurofins Scientific

Malvern Panalytical

Almac

Pfizer

Axplora

Aptuit

Porton

Pharmaron Beijing

Shanghai Haoyuan Chemexpress

Stapharma

API Drug Development Service Segment by Type

Captive Product Development Service

Commercial Product Development Service

API Drug Development Service Segment by Application

Small Biotechs Companies

Large Pharmaceutical Organizations

API Drug Development Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global API Drug Development Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the API Drug Development Service key companies, revenue, market share, and recent developments.

3. To split the API Drug Development Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions API Drug Development Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify API Drug Development Service significant trends, drivers, influence factors in global and regions.

6. To analyze API Drug Development Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global API Drug Development Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of API Drug Development Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of API Drug Development Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global API Drug Development Service industry.

Chapter 3: Detailed analysis of API Drug Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of API Drug Development Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of API Drug Development Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. API Drug Development Service Industry Trends Table 2. API Drug Development Service Industry Drivers Table 3. API Drug Development Service Industry Opportunities and Challenges Table 4. API Drug Development Service Industry Restraints Table 5. Global API Drug Development Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global API Drug Development Service Revenue Share by Company (2021-2026) Table 7. Global API Drug Development Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global API Drug Development Service Key Company Manufacturing Base & Headquarters Table 9. Global API Drug Development Service Company, Product Type & Application Table 10. Global API Drug Development Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global API Drug Development Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Captive Product Development Service Table 15. Significant Companies of Commercial Product Development Service Table 16. Global API Drug Development Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global API Drug Development Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global API Drug Development Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global API Drug Development Service Sales Value Share by Type (2021-2026) Table 20. Global API Drug Development Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Small Biotechs Companies Table 22. Significant Companies of Large Pharmaceutical Organizations Table 23. Global API Drug Development Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global API Drug Development Service Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global API Drug Development Service Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global API Drug Development Service Sales Value Share by Application (2021-2026) Table 27. Global API Drug Development Service Sales Value Share by Application (2027-2032) Table 28. Global API Drug Development Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global API Drug Development Service Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global API Drug Development Service Sales Value Share by Region (2021-2026) Table 31. Global API Drug Development Service Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global API Drug Development Service Sales Value Share by Region (2027-2032) Table 33. Global API Drug Development Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global API Drug Development Service Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global API Drug Development Service Sales Value Market Share by Country (2021-2026) Table 36. Global API Drug Development Service Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global API Drug Development Service Sales Value Market Share by Country (2027-2032) Table 38. Lonza Company Information Table 39. Lonza Business Overview Table 40. Lonza API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Lonza API Drug Development Service Product Portfolio Table 42. Lonza Recent Development Table 43. Patheon Company Information Table 44. Patheon Business Overview Table 45. Patheon API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Patheon API Drug Development Service Product Portfolio Table 47. Patheon Recent Development Table 48. Catalent Company Information Table 49. Catalent Business Overview Table 50. Catalent API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Catalent API Drug Development Service Product Portfolio Table 52. Catalent Recent Development Table 53. Carbogen Amcis Company Information Table 54. Carbogen Amcis Business Overview Table 55. Carbogen Amcis API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Carbogen Amcis API Drug Development Service Product Portfolio Table 57. Carbogen Amcis Recent Development Table 58. Sterling Pharma Solutions Company Information Table 59. Sterling Pharma Solutions Business Overview Table 60. Sterling Pharma Solutions API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Sterling Pharma Solutions API Drug Development Service Product Portfolio Table 62. Sterling Pharma Solutions Recent Development Table 63. Cambrex Company Information Table 64. Cambrex Business Overview Table 65. Cambrex API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Cambrex API Drug Development Service Product Portfolio Table 67. Cambrex Recent Development Table 68. CordenPharma Company Information Table 69. CordenPharma Business Overview Table 70. CordenPharma API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CordenPharma API Drug Development Service Product Portfolio Table 72. CordenPharma Recent Development Table 73. Eurofins Scientific Company Information Table 74. Eurofins Scientific Business Overview Table 75. Eurofins Scientific API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Eurofins Scientific API Drug Development Service Product Portfolio Table 77. Eurofins Scientific Recent Development Table 78. Malvern Panalytical Company Information Table 79. Malvern Panalytical Business Overview Table 80. Malvern Panalytical API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Malvern Panalytical API Drug Development Service Product Portfolio Table 82. Malvern Panalytical Recent Development Table 83. Almac Company Information Table 84. Almac Business Overview Table 85. Almac API Drug Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Almac API Drug Development Service Product Portfolio Table 87. Almac Recent Development Table 88. Pfizer Company Information Table 89. Pfizer Business Overview Table 90. Pfizer API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Pfizer API Drug Development Service Product Portfolio Table 92. Pfizer Recent Development Table 93. Axplora Company Information Table 94. Axplora Business Overview Table 95. Axplora API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Axplora API Drug Development Service Product Portfolio Table 97. Axplora Recent Development Table 98. Aptuit Company Information Table 99. Aptuit Business Overview Table 100. Aptuit API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Aptuit API Drug Development Service Product Portfolio Table 102. Aptuit Recent Development Table 103. Porton Company Information Table 104. Porton Business Overview Table 105. Porton API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Porton API Drug Development Service Product Portfolio Table 107. Porton Recent Development Table 108. Pharmaron Beijing Company Information Table 109. Pharmaron Beijing Business Overview Table 110. Pharmaron Beijing API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Pharmaron Beijing API Drug Development Service Product Portfolio Table 112. Pharmaron Beijing Recent Development Table 113. Shanghai Haoyuan Chemexpress Company Information Table 114. Shanghai Haoyuan Chemexpress Business Overview Table 115. Shanghai Haoyuan Chemexpress API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Shanghai Haoyuan Chemexpress API Drug Development Service Product Portfolio Table 117. Shanghai Haoyuan Chemexpress Recent Development Table 118. Stapharma Company Information Table 119. Stapharma Business Overview Table 120. Stapharma API Drug Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Stapharma API Drug Development Service Product Portfolio Table 122. Stapharma Recent Development Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. API Drug Development Service Product Image Figure 2. Global API Drug Development Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global API Drug Development Service Market Size (2021-2032) & (US$ Million) Figure 4. Global API Drug Development Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Captive Product Development Service Image Figure 8. Commercial Product Development Service Image Figure 9. Global API Drug Development Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global API Drug Development Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global API Drug Development Service Sales Value Share by Type (2021-2032) Figure 12. Small Biotechs Companies Image Figure 13. Large Pharmaceutical Organizations Image Figure 14. Global API Drug Development Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global API Drug Development Service Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global API Drug Development Service Sales Value Share by Application (2021-2032) Figure 17. Global API Drug Development Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global API Drug Development Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America API Drug Development Service Sales Value (2021-2032) & (US$ Million) Figure 20. North America API Drug Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe API Drug Development Service Sales Value (2021-2032) & (US$ Million) Figure 22. Europe API Drug Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific API Drug Development Service Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific API Drug Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America API Drug Development Service Sales Value (2021-2032) & (US$ Million) Figure 26. South America API Drug Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa API Drug Development Service Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa API Drug Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt API Drug Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt API Drug Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt API Drug Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Captive Product Development Service
  • Commercial Product Development Service
Applications
  • Small Biotechs Companies
  • Large Pharmaceutical Organizations
Companies covered
  • Lonza
  • Patheon
  • Catalent
  • Carbogen Amcis
  • Sterling Pharma Solutions
  • Cambrex
  • CordenPharma
  • Eurofins Scientific
  • Malvern Panalytical
  • Almac
  • Pfizer
  • Axplora
  • Aptuit
  • Porton
  • Pharmaron Beijing
  • Shanghai Haoyuan Chemexpress
  • Stapharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global API Drug Development Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global API Drug Development Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 API Drug Development Service Market Dynamics
  1. 2.1 API Drug Development Service Industry Trends
  2. 2.2 API Drug Development Service Industry Drivers
  3. 2.3 API Drug Development Service Industry Opportunities and Challenges
  4. 2.4 API Drug Development Service Industry Restraints
3 API Drug Development Service Market by Company
  1. 3.1 Global API Drug Development Service Company Revenue Ranking in 2025
  2. 3.2 Global API Drug Development Service Revenue by Company (2021-2026)
  3. 3.3 Global API Drug Development Service Company Ranking (2024-2026)
  4. 3.4 Global API Drug Development Service Company Manufacturing Base and Headquarters
  5. 3.5 Global API Drug Development Service Company Product Type and Application
  6. 3.6 Global API Drug Development Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global API Drug Development Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 API Drug Development Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 API Drug Development Service Market by Type
  1. 4.1 API Drug Development Service Type Introduction
  2. 4.1.1 Captive Product Development Service
  3. 4.1.2 Commercial Product Development Service
  4. 4.2 Global API Drug Development Service Sales Value by Type
  5. 4.2.1 Global API Drug Development Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global API Drug Development Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global API Drug Development Service Sales Value Share by Type (2021-2032)
5 API Drug Development Service Market by Application
  1. 5.1 API Drug Development Service Application Introduction
  2. 5.1.1 Small Biotechs Companies
  3. 5.1.2 Large Pharmaceutical Organizations
  4. 5.2 Global API Drug Development Service Sales Value by Application
  5. 5.2.1 Global API Drug Development Service Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global API Drug Development Service Sales Value by Application (2021-2032)
  7. 5.2.3 Global API Drug Development Service Sales Value Share by Application (2021-2032)
6 API Drug Development Service Regional Value Analysis
  1. 6.1 Global API Drug Development Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global API Drug Development Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global API Drug Development Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global API Drug Development Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America API Drug Development Service Sales Value (2021-2032)
  7. 6.3.2 North America API Drug Development Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe API Drug Development Service Sales Value (2021-2032)
  10. 6.4.2 Europe API Drug Development Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific API Drug Development Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific API Drug Development Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America API Drug Development Service Sales Value (2021-2032)
  16. 6.6.2 South America API Drug Development Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa API Drug Development Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa API Drug Development Service Sales Value Share by Country, 2025 VS 2032
7 API Drug Development Service Country-level Value Analysis
  1. 7.1 Global API Drug Development Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global API Drug Development Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global API Drug Development Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global API Drug Development Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA API Drug Development Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada API Drug Development Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico API Drug Development Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany API Drug Development Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France API Drug Development Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. API Drug Development Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy API Drug Development Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain API Drug Development Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia API Drug Development Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands API Drug Development Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries API Drug Development Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China API Drug Development Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan API Drug Development Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea API Drug Development Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India API Drug Development Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia API Drug Development Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia API Drug Development Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil API Drug Development Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina API Drug Development Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile API Drug Development Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia API Drug Development Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru API Drug Development Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia API Drug Development Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel API Drug Development Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE API Drug Development Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey API Drug Development Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran API Drug Development Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran API Drug Development Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt API Drug Development Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt API Drug Development Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt API Drug Development Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza API Drug Development Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza API Drug Development Service Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Patheon
  8. 8.2.1 Patheon Company Information
  9. 8.2.2 Patheon Business Overview
  10. 8.2.3 Patheon API Drug Development Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Patheon API Drug Development Service Product Portfolio
  12. 8.2.5 Patheon Recent Developments
  13. 8.3 Catalent
  14. 8.3.1 Catalent Company Information
  15. 8.3.2 Catalent Business Overview
  16. 8.3.3 Catalent API Drug Development Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Catalent API Drug Development Service Product Portfolio
  18. 8.3.5 Catalent Recent Developments
  19. 8.4 Carbogen Amcis
  20. 8.4.1 Carbogen Amcis Company Information
  21. 8.4.2 Carbogen Amcis Business Overview
  22. 8.4.3 Carbogen Amcis API Drug Development Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Carbogen Amcis API Drug Development Service Product Portfolio
  24. 8.4.5 Carbogen Amcis Recent Developments
  25. 8.5 Sterling Pharma Solutions
  26. 8.5.1 Sterling Pharma Solutions Company Information
  27. 8.5.2 Sterling Pharma Solutions Business Overview
  28. 8.5.3 Sterling Pharma Solutions API Drug Development Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sterling Pharma Solutions API Drug Development Service Product Portfolio
  30. 8.5.5 Sterling Pharma Solutions Recent Developments
  31. 8.6 Cambrex
  32. 8.6.1 Cambrex Company Information
  33. 8.6.2 Cambrex Business Overview
  34. 8.6.3 Cambrex API Drug Development Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cambrex API Drug Development Service Product Portfolio
  36. 8.6.5 Cambrex Recent Developments
  37. 8.7 CordenPharma
  38. 8.7.1 CordenPharma Company Information
  39. 8.7.2 CordenPharma Business Overview
  40. 8.7.3 CordenPharma API Drug Development Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CordenPharma API Drug Development Service Product Portfolio
  42. 8.7.5 CordenPharma Recent Developments
  43. 8.8 Eurofins Scientific
  44. 8.8.1 Eurofins Scientific Company Information
  45. 8.8.2 Eurofins Scientific Business Overview
  46. 8.8.3 Eurofins Scientific API Drug Development Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eurofins Scientific API Drug Development Service Product Portfolio
  48. 8.8.5 Eurofins Scientific Recent Developments
  49. 8.9 Malvern Panalytical
  50. 8.9.1 Malvern Panalytical Company Information
  51. 8.9.2 Malvern Panalytical Business Overview
  52. 8.9.3 Malvern Panalytical API Drug Development Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Malvern Panalytical API Drug Development Service Product Portfolio
  54. 8.9.5 Malvern Panalytical Recent Developments
  55. 8.10 Almac
  56. 8.10.1 Almac Company Information
  57. 8.10.2 Almac Business Overview
  58. 8.10.3 Almac API Drug Development Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Almac API Drug Development Service Product Portfolio
  60. 8.10.5 Almac Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer API Drug Development Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer API Drug Development Service Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Axplora
  68. 8.12.1 Axplora Company Information
  69. 8.12.2 Axplora Business Overview
  70. 8.12.3 Axplora API Drug Development Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Axplora API Drug Development Service Product Portfolio
  72. 8.12.5 Axplora Recent Developments
  73. 8.13 Aptuit
  74. 8.13.1 Aptuit Company Information
  75. 8.13.2 Aptuit Business Overview
  76. 8.13.3 Aptuit API Drug Development Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Aptuit API Drug Development Service Product Portfolio
  78. 8.13.5 Aptuit Recent Developments
  79. 8.14 Porton
  80. 8.14.1 Porton Company Information
  81. 8.14.2 Porton Business Overview
  82. 8.14.3 Porton API Drug Development Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Porton API Drug Development Service Product Portfolio
  84. 8.14.5 Porton Recent Developments
  85. 8.15 Pharmaron Beijing
  86. 8.15.1 Pharmaron Beijing Company Information
  87. 8.15.2 Pharmaron Beijing Business Overview
  88. 8.15.3 Pharmaron Beijing API Drug Development Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Pharmaron Beijing API Drug Development Service Product Portfolio
  90. 8.15.5 Pharmaron Beijing Recent Developments
  91. 8.16 Shanghai Haoyuan Chemexpress
  92. 8.16.1 Shanghai Haoyuan Chemexpress Company Information
  93. 8.16.2 Shanghai Haoyuan Chemexpress Business Overview
  94. 8.16.3 Shanghai Haoyuan Chemexpress API Drug Development Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Shanghai Haoyuan Chemexpress API Drug Development Service Product Portfolio
  96. 8.16.5 Shanghai Haoyuan Chemexpress Recent Developments
  97. 8.17 Stapharma
  98. 8.17.1 Stapharma Company Information
  99. 8.17.2 Stapharma Business Overview
  100. 8.17.3 Stapharma API Drug Development Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Stapharma API Drug Development Service Product Portfolio
  102. 8.17.5 Stapharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst